Abstract:Due to the tremendous heterogeneity of disease manifestations, many complex diseases that were once thought to be single diseases are now considered to have disease subtypes. Disease subtyping analysis, that is the identification of subgroups of patients with similar characteristics, is the first step to accomplish precision medicine. With the advancement of high-throughput technologies, omics data offers unprecedented opportunity to reveal disease subtypes. As a result, unsupervised clustering analysis has been widely used for this purpose. Though promising, the subtypes obtained from traditional quantitative approaches may not always be clinically meaningful (i.e. correlate with clinical outcomes). On the other hand, the collection of rich clinical data in modern epidemiology studies has the great potential to facilitate the disease subtyping process via omics data and to discovery clinically meaningful disease subtypes. Thus, we developed an outcome-guided Bayesian clustering (GuidedBayesianClustering) method to fully integrate the clinical data and the high-dimensional omics data. A Gaussian mixed model framework was applied to perform sample clustering; a spike-and-slab prior was utilized to perform gene selection; a mixture model prior was employed to incorporate the guidance from a clinical outcome variable; and a decision framework was adopted to infer the false discovery rate of the selected genes. We deployed conjugate priors to facilitate efficient Gibbs sampling. Our proposed full Bayesian method is capable of simultaneously (i) obtaining sample clustering (disease subtype discovery); (ii) performing feature selection (select genes related to the disease subtype); and (iii) utilizing clinical outcome variable to guide the disease subtype discovery. The superior performance of the GuidedBayesianClustering was demonstrated through simulations and applications of breast cancer expression data and Alzheimer's disease. An R package has been made publicly available on GitHub to improve the applicability of our method.

Supervised Bayesian Joint Graphical Model for Simultaneous Network Estimation and Subgroup Identification

Estimation of Multiple Networks with Common Structures in Heterogeneous Subgroups.

Robust Analysis of Cancer Heterogeneity for High‐dimensional Data

Bayesian Edge Regression in Undirected Graphical Models to Characterize Interpatient Heterogeneity in Cancer

Robust Bayesian Graphical Regression Models for Assessing Tumor Heterogeneity in Proteomic Networks

Network-based cancer heterogeneity analysis incorporating multi-view of prior information

Supervised Graph Clustering for Cancer Subtyping Based on Survival Analysis and Integration of Multi-Omic Tumor Data

A Bayesian approach to subgroup identification.

Incorporating prior information in gene expression network-based cancer heterogeneity analysis

Robust structured heterogeneity analysis approach for high-dimensional data

Multimodal Survival Ensemble Network: Integrating Genomic and Histopathological Insights for Enhanced Cancer Prognosis.

Combining heterogeneous subgroups with graph-structured variable selection priors for Cox regression

Regression‐based heterogeneity analysis to identify overlapping subgroup structure in high‐dimensional data

A Joint Graphical Model for Inferring Gene Networks Across Multiple Subpopulations and Data Types

Heterogeneity Analysis Via Integrating Multi-Sources High-Dimensional Data with Applications to Cancer Studies

Biomarker-guided heterogeneity analysis of genetic regulations via multivariate sparse fusion

Detecting Interactive Gene Groups for Single-Cell RNA-Seq Data Based on Co-Expression Network Analysis and Subgraph Learning

Identifying Oncogenes As Features for Clinical Cancer Prognosis by Bayesian Nonparametric Variable Selection Algorithm

Identifying Cancer Subtypes Using a Residual Graph Convolution Model on a Sample Similarity Network

Simultaneous clustering and estimation of networks in multiple graphical models

Outcome-guided Bayesian clustering for disease subtype discovery using high-dimensional transcriptomic data